Exact Mass: 475.99040080000003
Exact Mass Matches: 475.99040080000003
Found 38 metabolites which its exact mass value is equals to given mass value 475.99040080000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cefazolin sodium
C14H13N8NaO4S3 (476.01195780000006)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Ebrotidine
Ebrotidine is an H2 receptor antagonist with gastroprotective activity against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine, and approximately 10-fold greater than those of cimetidine. Ebrotidine has anti-Helicobacter pylori activity via inhibition of the urease enzyme and the proteolytic and mucolytic activities of the bacterium. However, its activity is synergistic with a number of antibacterial agents. Ebrotidine counteracts the inhibitory effects of H. pylori lipo-polysaccharides. C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection. IC50 Value: 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] Target: H2 receptor in vitro: Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. in vivo: Following intravenous administration to rats, ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner, ED50 being 0.21 and 0.44 mg/kg, respectively [2]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15\% in corpus and 26\% in antrum), by a rise in transmucosal potential difference (by 12\%), and by a decrease of mucosal microbleeding [3]. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30\% increase in mucus gel dimension, and showed 20\% increase in phospholipids, and the content of sulfo- (18\%) and sialomucins (21\%) [4].
Rhamnetin 3,3-disulfate
2,6-Bis(2,2,2-trifluoroethoxy)-3-{[3-(trifluoromethyl)-2-pyridyl]thio}benzonitrile
C17H9F9N2O2S (476.02410019999996)
(2R,3S,4R,5S,6S,7R)-2,3,5,6,7-pentachloropentadec-14-en-4-yl hydrogen sulfate
C15H25Cl5O4S (475.9916120000001)
Ebrotidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection. IC50 Value: 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] Target: H2 receptor in vitro: Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. in vivo: Following intravenous administration to rats, ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner, ED50 being 0.21 and 0.44 mg/kg, respectively [2]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15\% in corpus and 26\% in antrum), by a rise in transmucosal potential difference (by 12\%), and by a decrease of mucosal microbleeding [3]. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30\% increase in mucus gel dimension, and showed 20\% increase in phospholipids, and the content of sulfo- (18\%) and sialomucins (21\%) [4].
(4-Bromobutyl)(triphenyl)phosphonium bromide
C22H23Br2P (475.99040080000003)
sodium,formaldehyde,2-hydroxybenzenesulfonate,4-(4-hydroxyphenyl)sulfonylphenol
(R,R)-1,2-Bis(Trifluoromethanesulfonamido)-1,2-Diphenylethane
C16H14F6N2O4S2 (476.02991560000004)
6,13-dibromo-9,10-dimethoxy-1a,2,3,4,4a,5-hexahydro-1H-indeno[2,1-d]fluorene
C22H22Br2O2 (475.99864319999995)
Sitaxentan sodium
C18H14ClN2NaO6S2 (475.98794940000005)
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors.
(3-BROMOBUTYL)TRIPHENYLPHONIUM BROMIDE
C22H23Br2P (475.99040080000003)
1H,1H,2H,3H-PERFLUOROUNDEC-2-EN-1-OL
C11H5F17O (476.00689239999997)
bis(chlorophenyl)phenylsulphonium hexafluorophosphate(1-)
C18H13Cl2F6PS (475.97568000000007)
N,N-((1S,2S)-1,2-DIPHENYLETHANE-1,2-DIYL)BIS(1,1,1-TRIFLUOROMETHANESULFONAMIDE)
C16H14F6N2O4S2 (476.02991560000004)
(η-cumene)-(η-cyclopentadienyl)iron(II) hexafluoroantimonate
sodium,formaldehyde,4-hydroxybenzenesulfonic acid,4-(4-hydroxyphenyl)sulfonylphenolate
Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-((4-iodo-2-methylphenyl)amino)-
C18H16F3IN2O2 (476.02085819999996)
[10-(4-chlorophenyl)-2,6,8-trioxo-3,4a,5,5a,6,8,8a,9,9a,10-decahydro-5,9-methano[1,3]thiazolo[5,4:5,6]thiopyrano[2,3-f]isoindol-7(2H)-yl]acetic acid
2-({4-[(5-Chloro-1H-indol-2-YL)sulfonyl]piperazin-1-YL}carbonyl)thieno[3,2-B]pyridine 4-oxide
4-Bromo-3-(carboxymethoxy)-5-[4-[[oxo(3-pyridinyl)methyl]amino]phenyl]-2-thiophenecarboxylic acid
C19H13BrN2O6S (475.96776580000005)
2-[(2Z)-2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]methylidene]-4-oxo-1,3-thiazolidin-3-yl]-N-(2-chloropyridin-3-yl)acetamide
C20H14Cl2N4O2S2 (475.99352039999997)
[(2r,3s,4r,5s,6s,7r)-2,3,5,6,7-pentachloropentadec-14-en-4-yl]oxysulfonic acid
C15H25Cl5O4S (475.9916120000001)
(2,3,5,6,7-pentachloropentadec-14-en-4-yl)oxysulfonic acid
C15H25Cl5O4S (475.9916120000001)